Repros Therapeutics (RPRX) Granted FDA Type B meeting on Proellex
Tweet Send to a Friend
Up)
Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced that the FDA has agreed to a Type B meeting scheduled for the last half of May to discuss the Phase 3 development of Proellex® as a vaginally administered product for the treatment of uterine fibroids. During the meeting, Repros will discuss the proposed plans for a Phase 3 study, the FDA's requirements for the size of the safety population and the adequacy of the already completed preclinical studies to support a marketing application.
Once the meeting is held, the Company will report the outcome to the financial community in a timely fashion.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Once the meeting is held, the Company will report the outcome to the financial community in a timely fashion.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
- Oramed Pharma (ORMP) OK'd by FDA for ORMD-0801 IND
- Illumina (ILMN) Announces Full Launch of BaseSpace
Create E-mail Alert Related Categories
FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
